DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobsen, W.
Right arrow Articles by Christians, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobsen, W.
Right arrow Articles by Christians, U.

Vol. 28, Issue 11, 1369-1378, November 2000

Lactonization Is the Critical First Step in the Disposition of the 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitor Atorvastatin

Wolfgang Jacobsen, Bernd Kuhn, Andrea Soldner, Gabriele Kirchner, Karl-Fr. Sewing, Peter A. Kollman, Leslie Z. Benet, and Uwe Christians

Departments of Biopharmaceutical Sciences (W.J., A.S., L.Z.B., U.C.), and Pharmaceutical Chemistry (B.K., P.A.K.), School of Pharmacy, University of California, San Francisco, California; and Institut für Pharmakologie, Medizinische Hochschule Hannover, Hannover, Germany (G.K., K.-F.S., U.C.)

In an in vitro study, we compared the cytochrome P450 (CYP)-dependent metabolism and drug interactions of the acid and lactone forms of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor atorvastatin. Metabolism of atorvastatin acid and lactone by human liver microsomes resulted in para-hydroxy and ortho-hydroxy metabolites. Both substrates were metabolized mainly by CYP3A4 and CYP3A5. Atorvastatin lactone had a significantly higher affinity to CYP3A4 than the acid (Km: para-hydroxy atorvastatin, 25.6 ± 5.0 µM; para-hydroxy atorvastatin lactone, 1.4 ± 0.2 µM; ortho-hydroxy atorvastatin, 29.7 ± 9.4 µM; and ortho-hydroxy atorvastatin lactone, 3.9 ± 0.2 µM). Compared with atorvastatin acid, CYP-dependent metabolism of atorvastatin lactone to its para-hydroxy metabolite was 83-fold higher [formation CLint (Vmax/Km): lactone 2949 ± 3511 versus acid 35.5 ± 48.1 µl · min-1 · mg-1] and to its ortho-hydroxy metabolite was 20-fold higher (CLint: lactone 923 ± 965 versus acid 45.8 ± 59.1 µl · min-1 · mg-1). Atorvastatin lactone inhibited the metabolism of atorvastatin acid by human liver microsomes with an inhibition constant (Ki) of 0.9 µM while the Ki for inhibition of atorvastatin by atorvastatin lactone was 90 µM. Binding free energy calculations of atorvastatin acid and atorvastatin lactone complexed with CYP3A4 revealed that the smaller desolvation energy of the neutral lactone compared with the anionic acid is the dominant contribution to the higher binding affinity of the lactone rather than an entropy advantage. Because atorvastatin lactone has a significantly higher metabolic clearance and the lactone is a strong inhibitor of atorvastatin acid metabolism, it can be expected that metabolism of the lactone is the relevant pathway for atorvastatin elimination and drug interactions. We hypothesize that most of the open acid metabolites present in human plasma are generated by interconversion of lactone metabolites.

Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 PDA J Pharm Sci TechnolHome page
C. R. Palem, S. Patel, and V. B. Pokharkar
Solubility and Stability Enhancement of Atorvastatin by Cyclodextrin Complexation
PDA J. Pharm. Sci. Technol., May 1, 2009; 63(3): 217 - 225.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
N. Rao, B. Dvorchik, N. Sussman, H. Wang, K. Yamamoto, A. Mori, T. Uchimura, and P. Chaikin
A Study of the Pharmacokinetic Interaction of Istradefylline, a Novel Therapeutic for Parkinson's Disease, and Atorvastatin
J. Clin. Pharmacol., September 1, 2008; 48(9): 1092 - 1098.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. C. Goosen, J. N. Bauman, J. A. Davis, C. Yu, S. I. Hurst, J. A. Williams, and C.-M. Loi
Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid
Drug Metab. Dispos., August 1, 2007; 35(8): 1315 - 1324.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet
PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM
Drug Metab. Dispos., July 1, 2006; 34(7): 1175 - 1181.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet
Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 762 - 771.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
T. A. Nguyen, J. G. Diodati, and C. Pharand
Resistance to clopidogrel: A review of the evidence
J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1157 - 1164.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
T. C. Sarich, K.-M. Schutzer, H. Dorani, U. Wall, I. Kalies, L. Ohlsson, and U. G. Eriksson
No Pharmacokinetic or Pharmacodynamic Interaction Between Atorvastatin and the Oral Direct Thrombin Inhibitor Ximelagatran
J. Clin. Pharmacol., August 1, 2004; 44(8): 928 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. L. Lins, K. E. Matthys, G. A. Verpooten, P. C. Peeters, M. Dratwa, J.-C. Stolear, and N. H. Lameire
Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients
Nephrol. Dial. Transplant., May 1, 2003; 18(5): 967 - 976.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
W. C. Lau, L. A. Waskell, P. B. Watkins, C. J. Neer, K. Horowitz, A. S. Hopp, A. R. Tait, D. G.M. Carville, K. E. Guyer, and E. R. Bates
Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug-Drug Interaction
Circulation, January 7, 2003; 107(1): 32 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. A. Clarke and L. A. Waskell
The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin
Drug Metab. Dispos., January 1, 2003; 31(1): 53 - 59.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Prueksaritanont, C. Tang, Y. Qiu, L. Mu, R. Subramanian, and J. H. Lin
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
Drug Metab. Dispos., November 1, 2002; 30(11): 1280 - 1287.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Prueksaritanont, J. J. Zhao, B. Ma, B. A. Roadcap, C. Tang, Y. Qiu, L. Liu, J. H. Lin, P. G. Pearson, and T. A. Baillie
Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins
J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1042 - 1051.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Prueksaritanont, R. Subramanian, X. Fang, B. Ma, Y. Qiu, J. H. Lin, P. G. Pearson, and T. A. Baillie
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
Drug Metab. Dispos., May 1, 2002; 30(5): 505 - 512.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.